J&J Halts Covid-19 Vaccine Trial Due to Unexplained Illness
- Move follows temporary pause of AstraZeneca tests last month
- J&J plans to share more details after further investigation
This article is for subscribers only.
Johnson & Johnson halted clinical trials of its Covid-19 vaccine after a participant fell ill, the second time that a front-runner developer has paused testing in the race to create a viable immunization against the virus.
The participant’s illness is being evaluated, the New Brunswick, New Jersey-based company said late Monday, adding that it would share information after further investigation. J&J shares fell 2.4% in trading before U.S. exchanges opened. The vaccine is undergoing tests in as many as 60,000 volunteers from Peru to South Africa.